References:
1.	Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 2002. https://doi.org/10.1038/sj.onc.1205651
2.	Nishiyama A.Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021. https://doi.org/10.1016/j.tig.2021.05.002
3.	Rodriguez J, Frigola J, Vendrell E, Risques RA, Fraga MF, Morales C, et al. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res. 2006. https://doi.org/10.1158/0008-5472.CAN-06-0293
4.	Rauch TA, Zhong X, Wu X, Wang M, Kernstine KH, Wang Z, et al. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A. 2008. https://doi.org/10.1073/pnas.0710735105
5.	Hon GC, Hawkins RD, Caballero OL, Lo C, Lister R, Pelizzola M, et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res. 2012. https://doi.org/10.1101/gr.125872.111
6.	Chen RZ, Pettersson U, Beard C, Jackson-Grusby L.Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature. 1998. https://doi.org/10.1038/25779
7.	Oussalah A, Rischer S, Bensenane M, Conroy G, Filhine-Tresarrieu P, Debard R, et al. Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. EBioMedicine. 2018. https://doi.org/10.1016/j.ebiom.2018.03.029
8.	Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014. https://doi.org/10.1136/gutjnl-2012-304149
9.	Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998. 
10.	Rodriguez-Paredes M, Bormann F, Raddatz G, Gutekunst J, Lucena-Porcel C, Kohler F, et al. Methylation profiling identifies two subclasses of squamous cell carcinoma related to distinct cells of origin. Nat Commun. 2018. https://doi.org/10.1038/s41467-018-03025-1
11.	Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell. 2018. https://doi.org/10.1016/j.cell.2018.03.022
12.	Meunier L, Hirsch TZ, Caruso S, Imbeaud S, Bayard Q, Roehrig A, et al. DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. Hepatology. 2021. https://doi.org/10.1002/hep.31796
13.	Wang Y, Zhang M, Hu X, Qin W, Wu H.Wei M. Colon cancer-specific diagnostic and prognostic biomarkers based on genome-wide abnormal DNA methylation. Aging (Albany NY). 2020. https://doi.org/10.18632/aging.103874
14.	Hao X, Luo H, Krawczyk M, Wei W, Wang W, Wang J, et al. DNA methylation markers for diagnosis and prognosis of common cancers. Proc Natl Acad Sci U S A. 2017. https://doi.org/10.1073/pnas.1703577114
15.	Moore LD, Le T.Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013. https://doi.org/10.1038/npp.2012.112
16.	Hawe JS, Wilson R, Schmid KT, Zhou L, Lakshmanan LN, Lehne BC, et al. Genetic variation influencing DNA methylation provides insights into molecular mechanisms regulating genomic function. Nat Genet. 2022. https://doi.org/10.1038/s41588-021-00969-x
17.	Houlahan KE, Shiah YJ, Gusev A, Yuan J, Ahmed M, Shetty A, et al. Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nat Med. 2019. https://doi.org/10.1038/s41591-019-0579-z
18.	Li J, Xu B, He M, Zong X, Cunningham T, Sha C, et al. Control of Foxp3 induction and maintenance by sequential histone acetylation and DNA demethylation. Cell Rep. 2021. https://doi.org/10.1016/j.celrep.2021.110124
19.	Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018. https://doi.org/10.1038/s41588-018-0204-y
20.	Li H, Ma ZL, Li B, Pan YJ, Xiang JQ, Zhang YW, et al. Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non-small cell lung cancer patients. Cancer Med. 2021. https://doi.org/10.1002/cam4.4339
21.	Kim JG, Takeshima H, Niwa T, Rehnberg E, Shigematsu Y, Yoda Y, et al. Comprehensive DNA methylation and extensive mutation analyses reveal an association between the CpG island methylator phenotype and oncogenic mutations in gastric cancers. Cancer Lett. 2013. https://doi.org/10.1016/j.canlet.2012.11.022
22.	Brocks D, Assenov Y, Minner S, Bogatyrova O, Simon R, Koop C, et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. 2014. https://doi.org/10.1016/j.celrep.2014.06.053
23.	Mazor T, Pankov A, Johnson BE, Hong C, Hamilton EG, Bell RJA, et al. DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. Cancer Cell. 2015. https://doi.org/10.1016/j.ccell.2015.07.012
24.	Moody S, Senkin S, Islam SMA, Wang J, Nasrollahzadeh D, Cortez Cardoso Penha R, et al. Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. Nat Genet. 2021. https://doi.org/10.1038/s41588-021-00928-6
25.	Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020. https://doi.org/10.1038/s41586-020-1943-3
26.	Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ.Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013. https://doi.org/10.1016/j.celrep.2012.12.008
27.	Koh G, Degasperi A, Zou X, Momen S.Nik-Zainal S. Mutational signatures: emerging concepts, caveats and clinical applications. Nat Rev Cancer. 2021. https://doi.org/10.1038/s41568-021-00377-7
28.	Maki-Nevala S, Valo S, Ristimaki A, Sarhadi V, Knuutila S, Nystrom M, et al. DNA methylation changes and somatic mutations as tumorigenic events in Lynch syndrome-associated adenomas retaining mismatch repair protein expression. EBioMedicine. 2019. https://doi.org/10.1016/j.ebiom.2018.12.018
29.	Teschendorff AE.Relton CL. Statistical and integrative system-level analysis of DNA methylation data. Nat Rev Genet. 2018. https://doi.org/10.1038/nrg.2017.86
30.	Min JL, Hemani G, Hannon E, Dekkers KF, Castillo-Fernandez J, Luijk R, et al. Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation. Nat Genet. 2021. https://doi.org/10.1038/s41588-021-00923-x
31.	Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013. https://doi.org/10.1093/nar/gks1111
32.	Laurent A, Madigou T, Bizot M, Turpin M, Palierne G, Mahe E, et al. TET2-mediated epigenetic reprogramming of breast cancer cells impairs lysosome biogenesis. Life Sci Alliance. 2022. https://doi.org/10.26508/lsa.202101283
33.	Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, et al. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer Res. 2022. https://doi.org/10.1158/0008-5472.CAN-21-2576
34.	Cocce KJ, Jasper JS, Desautels TK, Everett L, Wardell S, Westerling T, et al. The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. Cell Rep. 2019. https://doi.org/10.1016/j.celrep.2019.09.032
35.	Li XL, Pongor L, Tang W, Das S, Muys BR, Jones MF, et al. A small protein encoded by a putative lncRNA regulates apoptosis and tumorigenicity in human colorectal cancer cells. Elife. 2020. https://doi.org/10.7554/eLife.53734
36.	Ramirez F, Ryan DP, Gruning B, Bhardwaj V, Kilpert F, Richter AS, et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 2016. https://doi.org/10.1093/nar/gkw257
37.	Pascual-Montano A, Carazo JM, Kochi K, Lehmann D.Pascual-Marqui RD. Nonsmooth nonnegative matrix factorization (nsNMF). IEEE Trans Pattern Anal Mach Intell. 2006. https://doi.org/10.1109/TPAMI.2006.60
38.	Brunet JP, Tamayo P, Golub TR.Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A. 2004. https://doi.org/10.1073/pnas.0308531101
39.	Guo J, Zhou Y, Xu C, Chen Q, Sztupinszki Z, Borcsok J, et al. Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers. Cancer Res. 2021. https://doi.org/10.1158/0008-5472.CAN-21-0086
40.	Burgess S.Thompson SG. Improving bias and coverage in instrumental variable analysis with weak instruments for continuous and binary outcomes. Stat Med. 2012. https://doi.org/10.1002/sim.4498
41.	Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010. https://doi.org/10.1016/j.molcel.2010.05.004
42.	Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, et al. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell. 2022. https://doi.org/10.1016/j.ccell.2021.11.012
43.	Filipski K, Scherer M, Zeiner KN, Bucher A, Kleemann J, Jurmeister P, et al. DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma. J Immunother Cancer. 2021. https://doi.org/10.1136/jitc-2020-002226
44.	Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018. https://doi.org/10.1038/s41591-018-0101-z
45.	Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019. https://doi.org/10.1038/s41591-019-0654-5
46.	Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017. https://doi.org/10.1016/j.cell.2017.09.028
47.	Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018. https://doi.org/10.1016/j.cell.2018.10.038
48.	Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012. https://doi.org/10.1038/nature11247
49.	Jiao X, Zhang S, Jiao J, Zhang T, Qu W, Muloye GM, et al. Promoter methylation of SEPT9 as a potential biomarker for early detection of cervical cancer and its overexpression predicts radioresistance. Clin Epigenetics. 2019. https://doi.org/10.1186/s13148-019-0719-9
50.	Wang YL, Qian J, Lin J, Yao DM, Qian Z, Zhu ZH, et al. Methylation status of DDIT3 gene in chronic myeloid leukemia. J Exp Clin Cancer Res. 2010. https://doi.org/10.1186/1756-9966-29-54
51.	Lopez-Otin C, Blasco MA, Partridge L, Serrano M.Kroemer G. The hallmarks of aging. Cell. 2013. https://doi.org/10.1016/j.cell.2013.05.039
52.	Bakulski KM, Dou J, Lin N, London SJ.Colacino JA. DNA methylation signature of smoking in lung cancer is enriched for exposure signatures in newborn and adult blood. Sci Rep. 2019. https://doi.org/10.1038/s41598-019-40963-2
53.	Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ, et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun. 2019. https://doi.org/10.1038/s41467-019-12159-9
54.	Meng Q, Lu YX, Ruan DY, Yu K, Chen YX, Xiao M, et al. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer. Mol Ther Nucleic Acids. 2021. https://doi.org/10.1016/j.omtn.2021.03.023
55.	Rooney MS, Shukla SA, Wu CJ, Getz G.Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015. https://doi.org/10.1016/j.cell.2014.12.033
56.	Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The Immune Landscape of Cancer. Immunity. 2018. https://doi.org/10.1016/j.immuni.2018.03.023
57.	Bian S, Hou Y, Zhou X, Li X, Yong J, Wang Y, et al. Single-cell multiomics sequencing and analyses of human colorectal cancer. Science. 2018. https://doi.org/10.1126/science.aao3791
58.	Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, et al. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. Cell. 2017. https://doi.org/10.1016/j.cell.2017.10.044
59.	Lee HO, Hong Y, Etlioglu HE, Cho YB, Pomella V, Van den Bosch B, et al. Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. Nat Genet. 2020. https://doi.org/10.1038/s41588-020-0636-z
60.	Facciabene A, Motz GT.Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012. https://doi.org/10.1158/0008-5472.CAN-11-3687
61.	Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A. 2005. https://doi.org/10.1073/pnas.0408197102
62.	Taylor DL, Jackson AU, Narisu N, Hemani G, Erdos MR, Chines PS, et al. Integrative analysis of gene expression, DNA methylation, physiological traits, and genetic variation in human skeletal muscle. Proc Natl Acad Sci U S A. 2019. https://doi.org/10.1073/pnas.1814263116
63.	Taylor K, Davey Smith G, Relton CL, Gaunt TR.Richardson TG. Prioritizing putative influential genes in cardiovascular disease susceptibility by applying tissue-specific Mendelian randomization. Genome Med. 2019. https://doi.org/10.1186/s13073-019-0613-2
64.	Meredith DM, Borromeo MD, Deering TG, Casey BH, Savage TK, Mayer PR, et al. Program specificity for Ptf1a in pancreas versus neural tube development correlates with distinct collaborating cofactors and chromatin accessibility. Mol Cell Biol. 2013. https://doi.org/10.1128/MCB.00364-13
65.	Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2009. https://doi.org/10.2217/epi.09.33
66.	Vaddavalli PL.Schumacher B. The p53 network: cellular and systemic DNA damage responses in cancer and aging. Trends Genet. 2022. https://doi.org/10.1016/j.tig.2022.02.010
67.	Zhang Y, Zhang D, Li Q, Liang J, Sun L, Yi X, et al. Nucleation of DNA repair factors by FOXA1 links DNA demethylation to transcriptional pioneering. Nat Genet. 2016. https://doi.org/10.1038/ng.3635
68.	Jing X, Liang H, Hao C, Hongxia L.Cui X. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer. Aging (Albany NY). 2019. https://doi.org/10.18632/aging.102250
69.	Choi Y, Luo Y, Lee S, Jin H, Yoon HJ, Hahn Y, et al. FOXL2 and FOXA1 cooperatively assemble on the TP53 promoter in alternative dimer configurations. Nucleic Acids Res. 2022. https://doi.org/10.1093/nar/gkac673
70.	Fernandez-Rozadilla C, Timofeeva M, Chen Z, Law P, Thomas M, Schmit S, et al. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. Nat Genet. 2022. https://doi.org/10.1038/s41588-022-01222-9
71.	Batra RN, Lifshitz A, Vidakovic AT, Chin SF, Sati-Batra A, Sammut SJ, et al. DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation. Nat Commun. 2021. https://doi.org/10.1038/s41467-021-25661-w
72.	Zhu T, Liu J, Beck S, Pan S, Capper D, Lechner M, et al. A pan-tissue DNA methylation atlas enables in silico decomposition of human tissue methylomes at cell-type resolution. Nat Methods. 2022. https://doi.org/10.1038/s41592-022-01412-7
73.	Wu J, Zhao W, Zhou B, Su Z, Gu X, Zhou Z, et al. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis. Genomics Proteomics Bioinformatics. 2018. https://doi.org/10.1016/j.gpb.2018.06.003


